Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (2016 - 2025)

Ironwood Pharmaceuticals' Shares Outstanding history spans 11 years, with the latest figure at $157.5 million for Q4 2019.

  • For Q4 2019, Shares Outstanding rose 2.02% year-over-year to $157.5 million; the TTM value through Dec 2019 reached $157.5 million, up 2.02%, while the annual FY2019 figure was $157.5 million, 2.02% up from the prior year.
  • Shares Outstanding for Q4 2019 was $157.5 million at Ironwood Pharmaceuticals, roughly flat from $156.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $157.5 million in Q4 2019 and bottomed at $14.0 million in Q4 2017.
  • The 5-year median for Shares Outstanding is $139.8 million (2018), against an average of $112.4 million.
  • The largest annual shift saw Shares Outstanding decreased 0.23% in 2015 before it surged 1018.04% in 2019.
  • A 5-year view of Shares Outstanding shows it stood at $15.9 million in 2015, then skyrocketed by 735.72% to $132.6 million in 2016, then rose by 2.89% to $136.5 million in 2017, then rose by 13.15% to $154.4 million in 2018, then increased by 2.02% to $157.5 million in 2019.
  • Per Business Quant, the three most recent readings for IRWD's Shares Outstanding are $157.5 million (Q4 2019), $156.8 million (Q3 2019), and $156.4 million (Q2 2019).